FDA Sunscreen Guidance: Absorption Data Is A MUsT For GRASE Review
This article was originally published in The Rose Sheet
The agency maintains maximal usage trials are essential in sunscreen ingredient GRASE assessments, despite industry objections that the tests have not been used for UV filters and no protocol is established. FDA’s final guidance closely mirrors its draft issued a year ago, which stakeholders projected would further delay consumer access to updated sunscreen products.
You may also be interested in...
The City Commission voted 6-1 at its Feb. 5 meeting to prohibit the sale of sunscreens formulated with oxybenzone and/or octinoxate beginning Jan. 1, 2021. That same day, Florida state Senator Linda Stewart proposed similar legislation that would push the effective date up to July 1, 2019, also citing the ingredients’ suspected role in coral declines.
Agency may be teaming with an outside party to conduct a maximal usage trial on sunscreen formulations. FDA guidance advises MUsTs to assess systemic exposure to sunscreen drug ingredients, but ingredient sponsors have been loath to invest in such tests due to questions about cost and viability.
GAO report requested by leadership of House and Senate committees with oversight of FDA adds evidence behind an argument that the agency's monograph process for sunscreen and other OTC ingredients should be changed substantially to facilitate making more pharmaceutical remedies available nonprescription.